Coastline Trust Co grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 7.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,375 shares of the medical research company’s stock after purchasing an additional 1,436 shares during the period. Coastline Trust Co’s holdings in Amgen were worth $3,871,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in AMGN. BlackRock Inc. raised its stake in shares of Amgen by 2.0% during the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock worth $8,979,621,000 after buying an additional 906,568 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of Amgen by 20,103.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after buying an additional 31,268,677 shares during the period. Northern Trust Corp raised its stake in shares of Amgen by 4.7% during the 4th quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock worth $1,787,470,000 after buying an additional 408,675 shares during the period. Geode Capital Management LLC raised its stake in shares of Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after buying an additional 482,760 shares during the period. Finally, Norges Bank acquired a new position in shares of Amgen during the 4th quarter worth approximately $1,283,248,000. Institutional investors and hedge funds own 77.27% of the company’s stock.

NASDAQ AMGN opened at $172.36 on Tuesday. Amgen, Inc. has a one year low of $166.30 and a one year high of $210.19. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.77 and a quick ratio of 2.53. The firm has a market capitalization of $101.68 billion, a P/E ratio of 11.97, a PEG ratio of 2.20 and a beta of 1.13.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The firm had revenue of $5.56 billion during the quarter, compared to the consensus estimate of $5.55 billion. During the same period in the prior year, the company earned $3.47 EPS. The firm’s revenue was up .1% compared to the same quarter last year. On average, sell-side analysts forecast that Amgen, Inc. will post 13.94 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $1.45 dividend. This represents a $5.80 annualized dividend and a yield of 3.37%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 40.28%.

Several research analysts have recently weighed in on the company. Mizuho set a $208.00 target price on Amgen and gave the stock a “buy” rating in a research note on Friday, April 12th. Royal Bank of Canada reaffirmed a “neutral” rating and set a $192.00 target price on shares of Amgen in a research note on Tuesday, May 21st. Oppenheimer set a $210.00 price objective on Amgen and gave the company a “buy” rating in a research note on Friday, May 24th. Citigroup raised Amgen from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $211.00 to $205.00 in a research note on Wednesday, May 22nd. Finally, Credit Suisse Group started coverage on Amgen in a research note on Monday, May 20th. They issued an “outperform” rating and a $208.00 price objective for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $208.35.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total value of $377,760.00. Following the completion of the sale, the director now directly owns 14,988 shares in the company, valued at approximately $2,830,933.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 6,000 shares of company stock valued at $1,115,580. 0.25% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: What are popular green investing opportunities?

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.